Are We PrEPared this Time? Ensuring a Swift Translation of Research into Community Impact

First approved in 2012, roll out of oral PrEP has been slow, uneven, and marked by troubling and unacceptable uptake disparities across race/ethnicity, gender and geography. In 2019, less than 25 percent of people eligible for PrEP in the US received a prescription. Late last year, the US FDA approved a new PrEP agent called Apretude, an injectable, longer-acting PrEP option. While hopes are high for this intervention, it is replete with challenges from both the user as well as the delivery sides of the equation.

The AIDS Foundation Chicago, AVAC and an array of speakers spoke on what must happen to ensure swift translation of positive research results into community impact. What follows are a set of resources from the webinar.

Resources

Recording / Slides

Sign On Letter
Requesting that the Biden administration include in his upcoming budget request $400 million to create a National PrEP Grant Program. Organizations can sign here.

Resources Shared

• Achieving Sufficient Scale of PrEP Use Is Critical to Ending the HIV Epidemic – O’Neill Institute for National and Global Health Law
• An Advocates’ Primer on Long-Acting Injectable Cabotegravir for PrEP — AVAC
• CDC2021 PrEP Update
• Convenience Comes at a Price: First injectable for HIV prevention isn’t cost-effective, analysis claims
• Data sources: AIDSVu, CDC NCHHSTP AtlasPlus, AHEAD
• Ensuring Compliance with New Federal USPSTF PrEP Guidance – O’Neill Institute for National and Global Health Law
• From Evidence to Implementation: Clarifications Around USPSTF Recommendations for HIV Pre-Exposure Prophylaxis (PrEP) - The American Journal of Managed Care
• HIV Prevention Has an Equity Problem. Here’s What Needs to Change – WebMD
• HIV Prevention: Better choice for better coverage – JIAS
• Injectable PrEP and COVID show we’re all in this together – Aidsmap
• Long-Acting HIV Treatment and Prevention Are Coming: Preparing for Potential Game Changers – amfAR
• National Clinician Consultation Center
• PrEPLine: 855-HIV-PrEP (855-448-7737)
• New Policy Proposal Seeks to Improve Access to Medications that Prevent HIV Infection
• Paying for PrEP – Advocacy in support
• Study supports pricing long-acting injectable cabotegravir to compete with generic oral HIV PrEP
• Supporting Young Black and Latinx Gay and Bisexual Men Is Critical to HIV and STI Prevention – O’Neill Institute for National and Global Health Law
• Storie Devereaux YouTube
• Stoviink Creatives (Storie Deveraux)
• Stoviink Creatives (Storie Deveraux)
• Webinar Playlist